Alopecia areata after COVID-19 vaccination

Gallo, Giuseppe; Mastorino, Luca; Tonella, Luca; Ribero, Simone; Quaglino, Pietro

doi:10.7774/cevr.2022.11.1.129

Cited by 28 publications

(42 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many case reports and studies of hair involvement reported after COVID‐19 vaccination have been published in the literature. 35 , 36 , 37 Nonetheless, since our study focused on cutaneous reactions, hair involvement after COVID‐19 vaccination was not examined separately. However, the current study also had several strengths, such as more than 95% of non‐local cutaneous reactions being diagnosed by a dermatologist and the participants being questioned through one‐to‐one interviews.…”

Section: Discussionmentioning

confidence: 99%

Cutaneous reactions after COVID‐19 vaccination in Turkey: A multicenter study

Cebeci

Erdoğan

Aktaş

et al. 2022

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Objectives In this study covering all of Turkey, we aimed to define cutaneous and systemic adverse reactions in our patient population after COVID‐19 vaccination with the Sinovac/CoronaVac (inactivated SARS‐CoV‐2) and Pfizer/BioNTech (BNT162b2) vaccines. Methods This prospective, cross‐sectional study included individuals presenting to the dermatology or emergency outpatient clinics of a total of 19 centers after having been vaccinated with the COVID‐19 vaccines. Systemic, local injection site, and non‐local cutaneous reactions after vaccination were identified, and their rates were determined. Results Of the 2290 individuals vaccinated between April 15 and July 15, 2021, 2097 (91.6%) received the CoronaVac vaccine and 183 (8%) BioNTech. Systemic reactions were observed at a rate of 31.0% after the first CoronaVac dose, 31.1% after the second CoronaVac dose, 46.4% after the first BioNTech dose, and 46.2% after the second BioNTech dose. Local injection site reactions were detected at a rate of 35.6% after the first CoronaVac dose, 35.7% after the second CoronaVac dose, 86.9% after the first BioNTech dose, and 94.1% after the second BioNTech dose. A total of 133 non‐local cutaneous reactions were identified after the CoronaVac vaccine (2.9% after the first dose and 3.5% after the second dose), with the most common being urticaria/angioedema, pityriasis rosea, herpes zoster, and maculopapular rash. After BioNTech, 39 non‐local cutaneous reactions were observed to have developed (24.8% after the first dose and 5% after the second dose), and the most common were herpes zoster, delayed large local reaction, pityriasis rosea, and urticaria/angioedema in order of frequency. Existing autoimmune diseases were triggered in 2.1% of the patients vaccinated with CoronaVac and 8.2% of those vaccinated with BioNTech. Conclusions There are no comprehensive data on cutaneous adverse reactions specific to the CoronaVac vaccine. We determined the frequency of adverse reactions from the dermatologist's point of view after CoronaVac and BioNTech vaccination and identified a wide spectrum of non‐local cutaneous reactions. Our data show that CoronaVac is associated with less harmful reactions while BioNTech may result in more serious reactions, such as herpes zoster, anaphylaxis, and triggering of autoimmunity. However, most of these reactions were self‐limiting or required little therapeutic intervention.

show abstract

Section: Discussionmentioning

confidence: 99%

Cutaneous reactions after COVID‐19 vaccination in Turkey: A multicenter study

Cebeci

Erdoğan

Aktaş

et al. 2022

J of Cosmetic Dermatology

View full text Add to dashboard Cite

show abstract

“…In fact, the recall of the previous episode of AA was not volunteered until the second visit. Most of available literature reported previous history of AA either remote or recent, however, May Lee et al, 2021, and Gallo et al, 2021, have reported cases for the first time [ 14 , 16 ].…”

Section: Discussionmentioning

confidence: 99%

Alopecia Areata Universalis Precipitated by SARS-CoV-2 Vaccine: A Case Report and Narrative Review

Abdalla¹,

Ebrahim²

2022

Cureus

View full text Add to dashboard Cite

Alopecia areata (AA) is a patchy autoimmune nonscarring hair loss. Various pathophysiological explanations are described with immune dysregulation being the most well established. In this report, we describe a 63-year-old lady with AA recurrence, in the form of AA universalis, after 32 years of remission, following administration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. We also briefly reviewed published cases with similar presentations after receiving the SARS-CoV-2 vaccine.

show abstract

“…Gallo et al’s report describes a further case—symptoms, which started 3 weeks after the vaccination, were limited to the scalp and beard. 11 This patient had no personal history of AA or other autoimmune disorders, nor any family history of AA.…”

Section: Postvaccinationmentioning

confidence: 98%